

← Correction: Replace Table 12-10 in book with Table 12-10 below

TABLE 12-10. β -Blockers and Combination α - and β -Blockers

| Drug | Trade name | Lipid solubility/ primary (secondary) routes of elimination | Usual dosage range, total mg/day (frequency per day) | Adverse effects and comments ^a |
|--|---------------------|---|--|--|
| β-blockers | | | | |
| Acebutolol ^{b,c} | Sectral | Low/H (R) | 200–800 (1) | Bronchospasm, bradycardia, and heart failure; may mask insulin-induced hypoglycemia; <i>less serious</i> : impaired peripheral circulation, insomnia, fatigue, decreased exercise tolerance, and hypertriglyceridemia, except agents with intrinsic sympathomimetic activity |
| Atenolol ^b | Tenormin | Low/R (H) | 25–100 (1) | |
| Betaxolol ^b | Kerlone | Low/H (R) | 5–20 (1) | |
| Bisoprolol fumarate ^b | Zebeta | Low/R (H) | 2.5–10 (1) | |
| Carteolol HCl ^c | Cartrol | Low/R | 2.5–10 (1) | |
| Metoprolol tartrate^b | Lopressor | Moderate/H (R) | 50–100 (2) | |
| Metoprolol succinate^b | Toprol-XL | Moderate/H (R) | 50–100 (1) | |
| Nadolol | Corgard | Low/R | 40–120 (1) | |
| Nebivolol^b | Bystolic | High/H (R) | 5–20 (1) | |
| Penbutolol sulfate ^c | Levitol | High/H (R) | 10–20 (1) | |
| Pindolol ^c | Visken | Moderate/H (R) | 10–60 (2) | |
| Propranolol HCl | Inderal | High/H | 40–160 (2) | |
| Timolol maleate | Inderal LA | High/H | 60–180 (1) | |
| | Blocadren | Low–moderate/H (R) | 20–40 (2) | |
| Combined α- and β-blockers | | | | |
| Carvedilol | Coreg | Moderate/bile into feces | 12.5–50 (2) | Postural hypotension, bronchospasm |
| Carvedilol | Coreg CR | Moderate/bile into feces | 10–80 (1) | Postural hypotension, bronchospasm |
| Labetalol | Normodyne, Trandate | Moderate/R (H) | 200–800 (2) | |

Adapted from JNC-VII, 2004.

Boldface indicates one of top 100 drugs for 2014 by units sold at retail outlets.

H, hepatic; R, renal.

a. Adverse effects listed are for the class of drugs.

b. Cardioselective.

c. Intrinsic sympathomimetic activity.

Parameters to monitor

- ECG
- Rebound hypertension
- Cholesterol levels
- Pulse (apical and radial)
- Glucose levels

FDA boxed warning

Abrupt withdrawal is not advised in patients with angina pectoris, coronary artery disease (CAD), or ischemic heart disease. Severe exacerbation of angina and the occurrence of MI and ventricular arrhythmias have been reported in angina patients following abrupt discontinuation. When discontinuation of